Actuate Therapeutics, Inc.

- Actuate Therapeutics' elraglusib, a GSK-3β inhibitor, receives FDA Rare Pediatric Disease Designation for Ewing sarcoma (EWS) treatment. - Early Phase 1/2 trial data shows promising anti-tumor activity, including durable complete responses in relapsed/refractory EWS patients. - The FDA designation may allow Actuate to receive a Priority Review Voucher upon NDA approval, potentially accelerating elraglusib's development. - Elraglusib is being evaluated in combination with topotecan/cyclophosphamide in a Phase 1/2 trial for pediatric patients with relapsed/refractory malignancies.

Nov 12, 2024

返回机构列表

Actuate Therapeutics, Inc.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（8）

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors

A clinical trial of a new drug known as 9-ING-41, that will take place inpatients with tumors or cancers that affect the blood and lymph system.9-ING-41 will be assessed as a standalone drug as well as being assessedwhen taken with chemotherapy drugs

Actuate 1901: 9-ING-41 in Myelofibrosis

9-ING-41 in Pediatric Patients With Refractory Malignancies.

A clinical trial of a new drug known as 9-ING-41, that will take place inpatients with tumors or cancers that affect the blood and lymph system.9-ING-41 will be assessed as a standalone drug as well as being assessedwhen taken with chemotherapy drugs

9-ING-41 in Patients With Advanced Cancers

Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3&beta;) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

药物批准

资讯

Elraglusib Granted FDA Rare Pediatric Disease Designation for Ewing Sarcoma

Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors